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ABSTRACT 20 
Co-amorphous mixtures have rarely been formulated as oral dosage forms, even though they have 21 
been shown to stabilize amorphous drugs in the solid state and enhance the dissolution properties of 22 
poorly soluble drugs.  23 
In the present study we formulated tablets consisting of either spray dried co-amorphous ibuprofen-24 
arginine or indomethacin-arginine, mannitol or xylitol and polyvinylpyrrolidone K30 (PVP). 25 
Experimental design was used for the selection of tablet compositions, and the effect of tablet 26 
composition on tablet characteristics was modelled. Multimodal non-linear imaging, including 27 
coherent anti-Stokes Raman scattering (CARS) and sum frequency/second harmonic generation 28 
(SFG/SHG) microscopies, as well as scanning electron microscopy, X-ray diffractometry and 29 
Fourier-transform infrared spectroscopy were utilized to characterize the tablets. 30 
The tablets possessed sufficient strength, but modelling produced no clear evidence about the 31 
compaction characteristics of co-amorphous salts. However, co-amorphous drug-arginine mixtures 32 
resulted in enhanced dissolution behaviour, and the PVP in the tableting mixture stabilized the 33 
supersaturation. The co-amorphous mixtures were physically stable during compaction, but the 34 
excipient selection affected the long term stability of the ibuprofen-arginine mixture. CARS and 35 
SFG/SHG proved feasible techniques in imaging the component distribution on the tablet surfaces, 36 
but possibly due to the limited imaging area, recrystallization detected with x-ray diffraction was 37 
not detected. 38 
KEYWORDS: Co-amorphous, amino acid, tablet, deformation, dissolution, multimodal non-linear 39 
imaging, CARS, SFG, SHG 40 
ABBREVIATIONS1  41 
                                                 
1 ACN, acetonitrile; ARG, arginine; CA, co-amorphous; CARS, coherent anti-Stokes Raman scattering; ER%, elastic 
recovery (%); FTIR, Fourier-transform infrared spectroscopy; HPLC, high-performance liquid chromatography; IBU, 
ibuprofen; IND, indomethacin; IR, infrared; KL, Kuentz-Leuenberger; PM, physical mixture; PVP, 
polyvinylpyrrolidone K30; SD, spray drying; SEM, scanning electron microscopy; SFG, sum frequency generation; 
TFA, trifluoro acetic acid; XRD, X-ray diffraction 
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1. INTRODUCTION 42 
The majority of drugs currently under development possess poor water solubility, which may lead 43 
to limited oral bioavailability as well as challenges in drug formulation and in vitro and in vivo 44 
testing during drug development [1,2]. Transformation of a crystalline drug to the amorphous form 45 
is a promising option for overcoming these challenges, since it has been shown to effectively 46 
increase the apparent solubility and dissolution rate of poorly soluble drugs [3-5]. However, the use 47 
of amorphous drugs has been limited due to their poor physical stability (i.e. tendency to 48 
recrystallize). 49 
To stabilize the amorphous form, different glass solution subtypes, i.e. polymeric amorphous solid 50 
dispersions, mesoporous silicon or silica-based glass solutions, and co-amorphous formulations 51 
have been introduced [4-9]. Of these formulations, the solid dispersions are the most extensively 52 
studied, but during the last decade the interest towards co-amorphous formulations (i.e. single-phase 53 
amorphous mixtures of the drug and two or more pharmaceutically active or inactive low molecular 54 
weight substances) has increased due to the potential for good physical stability, combination 55 
therapy and the reduced size of the final dosage form [4,7-10]. Additionally, co-amorphous 56 
formulations (especially co-amorphous salts) have been shown to increase dissolution rates, and in 57 
some studies even stabilize supersaturation, when compared to the crystalline or, more importantly, 58 
to the pure amorphous drugs [9-13].  59 
Being a relatively novel formulation approach, the co-amorphous mixtures have mainly been 60 
prepared by small scale methods, but in recent years also preparation methods that can be scaled up, 61 
such as spray drying (SD) and hot-melt extrusion, have been successfully utilized [9,14-19]. 62 
However, even though the co-amorphous systems are generally developed to improve the oral 63 
bioavailability, the development of oral dosage forms containing co-amorphous mixtures is still in 64 
its infancy [10,20]. Recently, some authors have successfully included co-amorphous mixtures in 65 
tablet formulations [21-23], but the deformation properties of the co-amorphous mixtures and the 66 
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effect of tablet composition on tablet properties has remained unexplored, even though the 67 
compaction properties of the co-amorphous components may differ from their crystalline 68 
counterparts and the excipients may significantly affect the deformation properties, mechanical 69 
strength, drug release as well as physical stability of the amorphous components [24-27]. 70 
Additionally, both Lenz et al. [21] and Petry et al. [22] investigated the physical stability of co-71 
amorphous indomethacin-arginine (IND-ARG) from ground tablets with conventional methods (X-72 
ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR)), even though the 73 
recrystallization may be more pronounced on the tablet surface, and it may be too otherwise limited 74 
to be observed with conventional methods [27,28].  75 
Non-linear optical imaging techniques, including coherent anti-Stokes Raman scattering (CARS) 76 
and sum frequency/second harmonic generation (SFG/SHG) microscopies, are relatively new 77 
imaging modalities with interesting capabilities. The general benefits of these techniques include 78 
label-free, chemically-specific signal, fast data-acquisition time and inherent non-destructive 79 
“confocal”- like imaging [29]. The label-free nature of CARS is based on the non-linear probing of 80 
molecular vibrational resonances [30], whereas materials with non-centrosymmetric structures 81 
generate SFG/SHG signals [31]. Most of the research in the use of non-linear optics has been 82 
focused on instrument development, however studies of the applications of non-linear optical 83 
imaging in different fields are increasing. Mostly, these techniques have been used in biomedical 84 
applications, where especially CH2 stretching of lipids has been probed with CARS [32], while 85 
collagen has been imaged with SHG [33]. However, pharmaceutical applications including solid-86 
state analysis of non-linear optical imaging have also been increasing [29]. For example CARS has 87 
been used to identify solid-state forms of IND on tablet surfaces [34,35] and to monitor the solid-88 
state changes of theophylline during dissolution [36]. On the other hand SFG/SHG, can be 89 
especially useful in solid-state analysis, since only non-centrosymmetric crystals produce SFG/SHG 90 
signals. SHG has been quantitatively used to analyse pharmaceutical solid-solid mixtures [37] and 91 
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has also been utilized in imaging, for example to visualize trace crystallinity in powder mixtures 92 
with a detection limit of 4 ppm [38]. In multimodal non-linear optical imaging, CARS and 93 
SFG/SHG can be simultaneously combined. It was recently shown that such a combination is well-94 
suited to the detection of different polymorphs and the amorphous form on tablet surfaces with high 95 
sensitivity [35]. Crystallisation processes during storage can be imaged in detail. While in that study 96 
tablets were composed of pure drug, the multimodal technique also has much potential for 97 
analysing relatively complex multicomponent tablets. Multimodal CARS and SFG/SHG imaging 98 
has not yet been used to image formulations containing both drug and excipient, nor changes in 99 
their crystallinity and component distribution upon storage.   100 
In the present study, we prepared tablets containing amorphous salts of ibuprofen (IBU) and ARG 101 
and IND and ARG, and employed multi-modal non-linear optical imaging and established 102 
analytical methods to explore the effect of formulation variables on pharmaceutical performance.  103 
The tablet compositions were selected with an experimental design that consisted of three factors, 104 
i.e. the amount of drug-ARG salt, the amount of polyvinylpyrrolidone K30 (PVP) and the sugar 105 
alcohol species. Our aim was to investigate the effect of the abovementioned variables on the 106 
compaction characteristics, on the mechanical properties of the tablets as well as on the drug release 107 
behaviour and the physical stability of the co-amorphous salts. Additionally, CARS and SFG/SHG 108 
were combined in order to explain compaction properties by visually detecting the drug and 109 
excipient distribution and to detect possible phase separation and re-crystallization on the surface of 110 
complex multi-component tablets during storage. 111 
2. MATERIALS AND METHODS 112 
2.1 Materials 113 
ARG (L-enantiomer) and PVP were purchased from Sigma-Aldrich Co. (St. Louis, USA) and γ-114 
IND from Hangzhou Dayanchem (Hangzhou, China). Racemic R,S-IBU and the sugar alcohols 115 
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(mannitol (Pearlitol® 200SD) and xylitol (Xylisorb® 200DC)) were kindly donated by Orion 116 
Corporation (Espoo, Finland) and Roquette (Lestrem, France), respectively. Glacial acetic acid 117 
(Riedel de Haën, Seelze, Germany), hydrochloric acid (HCl, 37 %; Riedel-de-Haën, Seelze, 118 
Germany), potassium chloride (J. T. Baker, Deventer, Holland), sodium acetate (Riedel-de-Haën, 119 
Seelze, Germany), sodium hydroxide (NaOH; VWR Chemicals, Leuven, Belgium), and potassium 120 
dihydrogen phosphate (KH2PO4; Merck, Darmstadt, Germany) were used in the preparation of the 121 
buffer solutions. During the storage of the samples, dry conditions were maintained with 122 
phosphorus pentoxide (P2O5), while approximately 33% RH was maintained with saturated 123 
magnesium chloride (MgCl2) solution. Ultrapurified water (class I; Elga Purelab Ultra, Elga 124 
LabWater, UK) was used in the high-performance liquid chromatography (HPLC) mobile phase as 125 
well as to prepare the drug-ARG solutions prior to the SD. Otherwise class II water (Elix 5, 126 
Millipore S.A.S., Molsheim, France) was used throughout the study. Acetonitrile (ACN; HPLC 127 
grade; VWR Chemicals, Leuven, Belgium and Fisher Chemical, Loughborough, UK) and trifluoro 128 
acetic acid (TFA; HPLC-grade; Sigma-Aldrich, Germany) were the other components of the high 129 
performance liquid chromatography (HPLC) mobile phase. 130 
2.2 Methods 131 
2.2.1 Preparation of the co-amorphous salts 132 
The co-amorphous IBU-ARG and IND-ARG salts were prepared by spray drying as described in 133 
our previous article [19]. Briefly, an amount of drug was dissolved in a corresponding amount of 134 
5% ARG-water solution in order to obtain a drug-ARG molar ratio of 1:1, and once the solution 135 
was visually clear, it was spray dried with a Büchi Mini Spray Dryer B-191 (Büchi Labortechnik 136 
AG, Flawil, Switzerland). The water content of the freshly prepared samples was measured in 137 
triplicate with a coulometric Karl-Fischer titrator (Mettler Toledo C30, Mettler-Toledo GmbH, 138 
Greifensee, Switzerland). After preparation, the co-amorphous systems were stored in brown glass 139 
jars under 4 °C 0% RH conditions until the tablets were prepared. 140 
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2.2.2 Tablet composition and experiment design 141 
The tablet mixture compositions (Table 1) were based on a 2-level full factorial experiment design 142 
with three centre points that was conducted with Modde Pro-software (11.0.1, MKS Umetrics AB, 143 
Sweden). The experimental factors were drug load, amount of PVP, and the sugar alcohol species, 144 
whereas the responses were tablet tensile strength, elastic recovery, 1/C-value from the Kuentz-145 
Leuenberger (KL) equation (Eq. 3, see section 2.2.5), the cumulative dissolved amount of drug after 146 
15 min (CDA15min), and the area under the cumulative dissolved drug amount-time curve after the 147 
2h dissolution study (AUC0-120min). The compaction force and the relative amount of the sugar 148 
alcohol were kept constant (20 kN and 60% (m/m) of the tablet mass, respectively). Thus, the tablet 149 
mass was changed according to the drug dose and the amount of PVP. 150 
2.2.3 Preparation of the powder mixtures 151 
The powder blends for tableting were prepared in a mortar by first mixing the drug-ARG mixture 152 
with PVP and then adding the sugar alcohol in two or three batches depending on the amount of the 153 
final mixture. The homogeneities of the prepared powder mixtures were investigated with two 154 
model formulations (B4 and N2) by dissolving five parallel tablets in 250 ml of phosphate buffer 155 
(pH 7.4) in ambient conditions and analysing the drug content with HPLC after 24h.  156 
2.2.4 Tablet preparation 157 
Flat faced tablets (diameter 13 mm) were compressed with a compaction simulator (PCS-1, 158 
PuuMan Ltd., Kuopio, Finland) using a double-sided sine wave compression profile (duration 1500 159 
ms). Due to high ejection forces, powder sticking and tablet fracturing occurred during preliminary 160 
studies without lubrication, and thus magnesium stearate was added to the die walls and lower 161 
punch using a brush prior to every compression except for the tablets for stability studies. The 162 
compaction force was set to approximately 20 kN with every formulation. The tablets were weighed 163 
immediately after compression, whereas the dimensions were measured the next day. 164 
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 2.2.5 Compaction characteristics 165 
The force-displacement data of five parallel compressions were collected and corrected according to 166 
the punch deformations. This corrected data was utilized to determine the relative density (ρ) of the 167 
different formulations at various compaction pressures according to Eq. 1: 168 
 𝜌 =
𝜌𝑎𝑝𝑝
𝜌𝑡,𝑚𝑖𝑥
 (1) 
where ρapp is the density at a certain pressure and ρt,mix is the true density of the formulation that 169 
was calculated according to Eq. 2: 170 
 𝜌𝑡,𝑚𝑖𝑥 =
𝑤1 +⋯+𝑤𝑛
𝑤1
𝜌𝑡1
+⋯+
𝑤𝑛
𝜌𝑡𝑛
 (2) 
Here, w denotes weight fraction and ρt the true density, while the subscripts 1 and n refer to the 171 
different components of the formulation [40]. The ρt-values of the single components were obtained 172 
from the literature [41-43].  173 
The deformation properties of the different formulations were evaluated using the KL-equation (Eq. 174 
3): 175 
 𝜎 =
1
𝐶
[𝜌𝑐 − 𝜌 − (1 − 𝜌𝑐) ln (
1 − 𝜌
1 − 𝜌𝑐
)] (3) 
where σ is the compaction pressure, 1/C is a plasticity parameter (interpretation corresponds to the 176 
yield pressure from Heckel equation) and ρc is the critical relative density (relative density where 177 
mechanical rigidity emerges in the powder bed) [44,45]. To determine the ρc, the pressure 178 
susceptibility (χp; susceptibility of the powder bed to external pressure) at each data point was 179 
calculated using Eq. 4 after which the χp was plotted against relative density as described by Kuentz 180 
and Leuenberger [44]. The ρc was considered as the pressure where the χp began to systematically 181 
decrease with increasing ρ (an example shown in the supplementary material (Figures S1A and 182 
S1B)). Finally, the constant C was obtained by fitting Eq. 3 to the σ vs. ρ data (Figure S1C) using 183 
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nonlinear regression that was conducted with SigmaPlot 14.0 (Systat Software Inc., San Jose, CA, 184 
USA).  185 
 𝑑𝜌
𝑑𝜎
= 𝜒𝑝(1 − 𝜌) (4) 
 186 
The percentage of axial elastic recovery (ER%) was obtained by using Eq. 5 [46]: 187 
 
𝐸𝑅% =
𝐻 − 𝐻𝑐
𝐻𝑐
× 100% (5) 
where H is the tablet height measured 24h after compression and Hc is the tablet height at maximum 188 
pressure. 189 
A universal tester (CT-5 tester, Engineering Systems, Nottingham, England) was used to determine 190 
the crushing strengths of the tablets (n = 5) 24h after the compression. The tensile strengths (σ) 191 
were calculated according to Eq. 6: 192 
 𝜎 =
2𝑃
𝜋𝐷𝑡
 (6) 
where P is the applied load (crushing strength), D is the tablet diameter, and t is the tablet thickness 193 
[47].  194 
2.2.6 Dissolution studies 195 
The dissolution studies were performed with Sotax AT6 and Sotax AT7 smart dissolution testers 196 
(Sotax AG, Basel, Switzerland) equipped with paddle stirrers. Each tablet formulation was studied 197 
in triplicate in 500 ml of dissolution medium (pH 1.2 HCl buffer for IBU-tablets and pH 5.0 acetate 198 
buffer for IND tablets) that was kept at 37 °C and stirred at 50 rpm. The duration of the study was 2 199 
hours, the samples were taken at 5 min, 10 min, 15 min, 30 min, 60 min, 90 min, and 120 min time 200 
points, and the sample volume (5 ml) was replaced with buffer solution. The samples were filtered 201 
through 0.22 µm membrane filters (Syringe filter 30 mm Dia, PES 0.22 µm Membrane, Sterile, 202 
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Porvair Sciences, Leatherhead, UK), and the drug concentration was analysed with HPLC (see 203 
section 2.2.7). Prior to the HPLC analysis, the samples were diluted with ACN to reach ACN/H2O-204 
ratio of 70/30, and if necessary, further dilution was conducted with 70/30 ACN/H2O mixture to 205 
obtain drug concentrations below 100 µg/ml.  206 
The effect of the formation of amorphous state and the effect of ARG on the dissolution behaviour 207 
of the drugs were investigated by performing the 2h dissolution studies with tablets corresponding 208 
to B4 and N2 formulations but containing either physical mixtures of the crystalline drug and ARG 209 
or only the crystalline drug (ARG replaced by mannitol) instead of the co-amorphous salt. 210 
Additionally, to investigate the effect of PVP on the supersaturation stability of the co-amorphous 211 
salts, a 24h dissolution study was conducted with B4- and N2-formulations as well as with 212 
formulations corresponding to B4 and N2, but in which the PVP was replaced with excess mannitol. 213 
In these studies, the samples were taken at 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 214 
24 h time points. 215 
2.2.7 HPLC 216 
The HPLC equipment consisted of Gilson 321 pump and Gilson UV-vis 151 detector (Gilson Inc., 217 
Middleton, WI, USA), Gilson 234 auto injector (Gilson, Roissy-en-France, France), and a reversed 218 
phase column (Phenomenex Gemini NX 5u C18 110A, 250x4, 60 mm, sr. nr. 590531-19, USA) 219 
with a pre-column. The mobile phase (70/30 ACN/H2O acidified with 0.1% TFA) flow rate was 1.2 220 
ml/min and the detection wavelengths were 221 nm for IBU and 225 nm for IND. The standard 221 
solutions (1, 5, 25, 50, 75, and 100 µg/ml) were prepared in 70/30 ACN/H2O-mixture and measured 222 
with HPLC to obtain standard lines that were linear (R2 > 0.997) in the examined concentration 223 
range. 224 
2.2.8 Tablet characterization 225 
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The tablet formulations were stored under 25 °C/33% RH to investigate the effect of compaction 226 
and tablet composition on the physical stability of co-amorphous salts. XRD and FTIR were used as 227 
standard methods to detect re-crystallization during the 20-week test period.  228 
X-ray diffractograms were collected from intact tablet surfaces using a Bruker D8 Discover 229 
diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) with Cu Κα radiation (λ = 1.54 Å) and a 230 
motorized slit. An acceleration voltage of 40 kV and current of 40 mA were used to perform a scan 231 
between 5 and 35° 2θ with a scan speed of 0.1 s/step and step size of 0.011°.  DIFFRAC.V3-232 
software (Bruker AXS GmbH) was utilized for data collection. 233 
The attenuated total reflectance (ATR) FTIR measurements were conducted with Thermo Nicolet 234 
Nexus 8700 spectrometer (Thermo Electron Corp., Madison, WI, USA) and with Nicolet iS50 FT-235 
IR spectrometer (Thermo Scientific, Madison, WI, USA). The spectra were collected over a 236 
wavenumber range of 650-4000 cm-1 as an average of 64 scans with the resolution of 4 cm-1. 237 
OMNIC-software (Thermo Scientific) was used for data collection and analysis.  238 
Additionally, CARS and SFG/SHG microscopies were utilized as more novel non-linear imaging 239 
methods to characterize the raw materials and to detect phase separation and recrystallization on the 240 
tablet surface as well as to image the drug-excipient distribution on the tablet surface. A Leica TCS 241 
SP8 CARS microscope (Leica Microsystems, Wetzlar, Germany) was used. Briefly, the imaging 242 
system consisted of an inverted microscope with a laser-scanning confocal scan-head and 243 
photomultiplier tube (PMT) and GaAsP hybrid (HyD) photodetectors. The Stokes beam (ωS) for 244 
CARS excitation was emitted from a Nd:YVO4 solid-state laser (1064.5 nm) (picoEMERALD
®, 245 
APE, Berlin, Germany). Laser source was integrated with an optical parametric oscillator (OPO) 246 
that generated tunable pump/probe beams (ωp and ωpr).The bandwidth of the Stokes beam (ωS) was 247 
about 2-3 cm-1 and the repetition rate was 80 MHz. The pulse duration was 7 ps for the Stokes and 248 
5-6 ps for the pump (ωp) and probe beams (ωpr). The pump beam wavelength can be tuned so that 249 
the energy difference between these beams corresponds to some molecular vibrational resonance. 250 
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The vibration is then probed with a probe photon, which can originate from the same beam as the 251 
pump photon. These beams are coherently driven into the sample and wave mixing results in 252 
generation of the fourth, blue-shifted, anti-Stokes photon (ωas), which is then detected. A water-253 
immersion objective (25× 0.95 NA) HCX IRAPO L (Leica) was used to focus the light onto the 254 
sample that was placed on a microscope slide No. 1.5. Epi-CARS detection was used to collect anti-255 
Stokes signal using a nondescanned PMT detector, while another nondescanned PMT detector was 256 
simultaneously used to collect epi-directed SFG/SHG signals with the bandpass filter 465 nm ± 85 257 
nm. HeNe laser (633 nm) was also used to visualize the tablet surfaces as reflected light was 258 
detected with a PMT detector. Images of 512 × 512 or 1024 × 1024 pixels were acquired with a 259 
pixel dwell time of 1.2 µs (scanning speed 400 Hz, line average 2). For the spectroscopic analysis, 260 
the wavelength of the pump beam was systematically changed 33 times from 893 nm to 925 nm 261 
covering the CARS shifts between 1804 cm-1 and 1417 cm-1. The acquisition time for each spectral 262 
scan was approximately 15 mins. CARS spectra in the figures are offset for clarity. Contrast was 263 
adjusted individually for each image. The Leica Application Suite Advanced Fluorescence 264 
(LASAF) was used for image acquisition and processing together with Fiji ImageJ (open-source 265 
distribution), GNU Image Manipulation Program v2 (open-source distribution) and Origin 2018 266 
(OriginLab, Northampton, Massachusetts, USA). RGB color images based on PCA were generated 267 
as described elsewhere using MATLAB R2016a (MathWork, MA, USA) [35]. Briefly, spectral data 268 
was mean centered and SNV corrected and the PC score values were normalized so that the 269 
minimum PC score value was set to 0 and the maximum score value to 1 and all values in between 270 
scaled linearly. PC1, PC2, and PC3 scores are represented by red, green, and blue coloring, 271 
respectively. 272 
To verify the morphological aspects observed with CARS, the fresh and stored (6 months) tablets as 273 
well as the spray dried drug-ARG powders were imaged with scanning electron microscopy (SEM). 274 
The morphology of the spray dried particles was micrographed with a field emission scanning 275 
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electron microscope (Zeiss Sigma HD VP, Carl Zeiss NTS, Cambridge, UK) using Everhart-276 
Thornley type secondary electron detector and a 30 µm aperture in high vacuum with acceleration 277 
voltage of 4 kV. With the tablets, the images were obtained under low vacuum conditions (15 Pa 278 
chamber pressure with dry nitrogen gas) with a VPSE G3 detector (Carl Zeiss NTS, Cambridge, 279 
UK) and an acceleration voltage of 10 kV. The low vacuum (higher gas pressure) conditions were 280 
used with the tablets, because the tablet height (2-3 mm) and the porous structure of the tablets 281 
including microfractures decreased the electric conductivity of the specimen. The charge due to the 282 
electron beam was eliminated with the nitrogen gas medium. 283 
2.2.9 Statistical analysis 284 
The effect of the selected tablet composition variables (factors) on the tablet properties (responses) 285 
were investigated with multiple linear regression (MLR) using MODDE Pro-software (11.0.1, MKS 286 
Umetrics AB, Sweden). A separate model was created for each response, and the non-significant 287 
interaction terms were excluded to provide the best possible model. The goodness of fit (R2) and 288 
goodness of prediction (Q2) were utilized to evaluate the models. In a good model, R2 should gain 289 
values close to 1, whereas a Q2 above 0.5 indicates good predicting power [48,49].    290 
GraphPad Prism 5.03 (GraphPad Software Inc., La Jolla, USA) was used for the determination of 291 
the AUC0-120mins and to conduct single-factor ANOVA with Tukey’s post-hoc test. The results of 292 
the statistical analyses were considered significant if p < 0.05.  293 
3. Results and discussion 294 
3.1 Tablet preparation 295 
3.1.1 Spray drying 296 
The spray drying of IBU-ARG solution resulted in white and loosely packed powder, whereas the 297 
spray dried IND-ARG powder was yellow and slightly denser packed. Both of the powders were 298 
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rather cohesive and non-free flowing and, according to the SEM images (Figure 1), the spray dried 299 
particles were spherical in shape and possessed diameters from less than 1 µm to a few dozens of 300 
micrometres, which is typical for spray dried materials [50]. The average yields of the spray drying 301 
were 31% with IND-ARG and 42% with IBU-ARG, which were similar with the values of our 302 
recent study (29.2%-34.4% [19]) but lower than the yield reported by Jensen et al. (~70% [16]). 303 
Additionally, the moisture contents of the freshly prepared powders (2.8±0.6% (IBU-ARG) and 304 
3.3±0.2% (IND-ARG)) were close to those reported previously for spray-dried IND-amino acid 305 
mixtures (3-4% [16]), and this amount of water is probably due to the water reuptake from the 306 
environment rather than incomplete drying, since similar values were also measured from ball-307 
milled samples [16].  308 
3.1.2 Preparation of the powder mixtures and tablet compaction 309 
The prepared drug-ARG-PVP-sugar alcohol mixtures were homogenous, at least in terms of drug 310 
content (tested with B4- and N2-formulations), since relative standard deviations of the released 311 
drug amounts between the parallel tablets were 5.7% with B4 and 4.0% with N2. However, neither 312 
of the formulations released the full drug dose (84% and 91% released from B4 and N2, 313 
respectively). The discrepancy between the theoretical drug content and actual released drug 314 
amount from B4 and N2 formulations may indicate that the poor flow properties of the spray dried 315 
mixtures resulted in challenges in the mixing process, i.e. sticking of the drug-ARG mixtures onto 316 
the weighing boats, mixing cards and onto the rough mortar surfaces, rather than uneven drug-ARG 317 
distribution in the powder mixture. Lenz et al. [21] avoided this challenge with spray dried IND-318 
ARG by combining it in a premixture with colloidal silicon dioxide that improved the powder flow 319 
properties and probably decreased the surface adherence of IND-ARG. However, the additional 320 
formulation components might have overcomplicated the analyses performed in the present study, 321 
and thus, no premixture was prepared. 322 
3.2 Tablet properties 323 
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3.2.1 Mechanical properties 324 
The exact values for variables describing the mechanical properties of the different formulations are 325 
presented in the supplementary material (Table S1). The tablets containing IND-ARG (N-326 
formulations) were slightly stronger than those containing IBU-ARG (B-formulations), but between 327 
corresponding formulations the difference was statistically significant only with pairs B3-N1 and 328 
B8-N4. With elastic recovery, no clear trend could be seen between the B and N formulations. The 329 
plasticity parameter (1/C) was significantly higher with every N formulation when compared to the 330 
corresponding (i.e. B1-N5, B2-N6, B3-N1, B4-N2, B5-N7, B6-N8, B7-N3, B8-N4) B formulations. 331 
Also, the ρc values were slightly higher with IND-ARG formulations, but since the same value was 332 
used for every parallel tablet, no statistical analysis could be made. 333 
The tensile strengths (1.9-3.5 MPa; Table S1) of the tablets produced in the present study with a 334 
compaction force of 20 kN (compaction pressure ~150 MPa) were in agreement with observations 335 
of Lenz et al. [21], who reported tensile strengths of 2.0 and 4.5 MPa for tablets consisting of spray 336 
dried IND-ARG, mannitol, croscarmellose sodium, colloidal silicon dioxide and magnesium 337 
stearate that were compressed under pressures of 82.3 and 198.6, MPa respectively. The modelling 338 
of the effect of the tablet composition on tensile strength was challenging especially with B-339 
formulations as indicated by summary of fit plots in the supplementary material (Figure S2), which 340 
can probably be explained by the low variation in tensile strength values together with the relatively 341 
large deviation between the parallel measurements. However, as observed also in previous research, 342 
mannitol formed stronger tablets than xylitol (Figure 2) [51]. Other main factors were insignificant. 343 
Additionally, despite the one significant interaction factor for the N-formulations (Figures 2 and 3 344 
(1.)), the direction of the changes in tensile strength, caused by varied tablet composition, were well 345 
estimated by the significant main factor.  346 
According to Tanner et al. [52], elastic recovery values between inelastic (e.g. glucose or calcium 347 
hydrogen phosphate) and highly elastic (e.g. starch) materials can vary from 1 to 18%. Thus, the 348 
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axial elastic recovery percentages obtained in the present study indicate that both B and N 349 
formulations possessed low or moderate elasticity. Additionally, even though elastic recovery as 350 
well as other compaction characteristics may depend not only on the material properties but also on 351 
the processing factors such as compaction force or speed, the elastic behaviour of the B and N 352 
formulations were in accordance with those reported for the single components [53-59].  353 
The model characteristics R2 and Q2 (Figure S2) indicated that the modelling of the effect of tablet 354 
composition on the elastic recovery could be more successful than the modelling of tensile strength.  355 
The model prediction of decreasing elasticity with increasing amount of drug-ARG mixture (Figure 356 
2) could be explained by the more efficient coverage of the excipient particles by the drug-ARG 357 
mixture, which could enhance particle bonding either by increased plasticity or adsorbance of water 358 
as observed with spray dried lactose [24,60].  However, due to the inconsistencies between the 359 
models of B and N formulations (opposite effect of sugar alcohol species on the ER% (Figure 2), no 360 
significant interactions in model for B formulations (Figure 2) vs. highly significant interactions 361 
with N formulations (Figures 2 and S3)), the conclusions concerning the effect of tablet 362 
composition on the elastic recovery must be made with caution. 363 
In this study, the KL-equation was utilized instead of the widely used Heckel equation to evaluate 364 
the deformation properties due to its suggested better reliability [45]. According to R2 and Q2 values 365 
(Figure S2), the 1/C value could be modelled reliably for both B and N formulations. Additionally, 366 
the interaction plots (Figure 3 (2. and 3.)) indicated that the direction of the change in the 1/C value 367 
could be predicted reasonably well with the main factors. The sugar alcohol species had the most 368 
prominent effect on the 1/C value (Figure 2), which could again be expected due to their high 369 
proportion in the tablets. Xylitol resulted in lower 1/C values than mannitol, indicating higher 370 
plasticity [45]. This seems contradictory with previously reported deformation properties of primary 371 
mannitol and xylitol particles, but may be explained by sodium carboxymethyl cellulose (~2%) 372 
included in Xylisorb® 200DC, which lowered the yield pressure of metformin hydrochloride, when 373 
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co-spray dried with the drug [51,61]. In addition to the sugar alcohol species, both amount of drug-374 
ARG mixture and amount of PVP affected the plasticity of the powder mixtures (Figure 2). The 375 
linear regression analyses between 1/C values of formulations containing low and high percentages 376 
(instead of absolute amounts) of drug-ARG mixture or PVP further indicated increased plasticity 377 
with an increasing proportion of drug-ARG mixture (slopes: -6.9 (B2-B5), -0.04 (B4-B7), -8.0 (N2-378 
N3) and -3.2 (N6-N7)) and a decrease in plasticity with an increase in the proportion of PVP 379 
(slopes: 6.9 (B2-B5), 0.04 (B4-B7), 7.9 (N2-N3) and 3.1 (N6-N7)). The effect of drug-ARG amount 380 
on plasticity was consistent with previous studies in which plasticity increased with amorphous 381 
components [24,62-64], but the increase in the plasticity with the decrease in the amount of PVP 382 
was inconsistent with its previously reported plastic nature [65]. However, in the present study, the 383 
increase PVP proportion accompanied a decrease in the amount of the apparently plastic drug-ARG 384 
mixture, which may explain the inconsistency.  385 
3.2.2 Dissolution properties 386 
The cumulative amount of dissolved drug increased up to 30 min, after which it remained steady or 387 
began to decrease (Figure 4). None of the B-formulations released the full drug dose, whereas with 388 
the N-formulations six out of nine tablets exhibited over 90% drug release.  389 
The CDA15min and AUC0-120min values of the different formulations are presented in the 390 
supplementary material (Table S2). Since the B formulations were unable to release the full drug 391 
dose, there was only limited deviation between the AUC0-120min values of the B-formulations. 392 
However, the deviation was more pronounced in the CDA15min value between B formulations as 393 
well as in both AUC0-120min and CDA15min values between the N formulations. Thus, only a rather 394 
poor model (Q2-value 0.23) could be formed to predict the effect of different factors on the AUC0-395 
120 of the B-formulations (not further analysed) but modelling of the CDA15min of B formulations as 396 
well as AUC0-120min and CDA15min of N formulations was more successful (Q
2-values of 0.58, 0.75 397 
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and 0.82, respectively (Figure S4)). As with the models predicting the mechanical properties, most 398 
of the interaction plots (Figure 5) of the AUC0-120 and CDA15min models revealed that the direction 399 
of the change in the response could be predicted by the main coefficients, but the magnitude of the 400 
change may be dependent on another interacting factor. 401 
According to the model, the amount of drug-ARG mixture and PVP were the most prominent 402 
factors affecting the AUC0-120min and CDA15min of the N-formulations (Figure 6). The increase in 403 
AUC0-120min by increasing the IND-ARG amount was expected, since this factor described the drug 404 
load instead of relative drug amount. Surprisingly, the model showed a negative effect of increasing 405 
amount of PVP on both AUC0-120min and CDA15min, even though PVP has been reported to enhance 406 
the dissolution properties and stabilize the supersaturation of IND both freely in solution and in 407 
solid dispersions [66-68], and, also in the present study, the ability of PVP to stabilize the 408 
supersaturation of IND was clearly demonstrated in the 24h dissolution test with N2 formulations 409 
containing and lacking PVP (Figure 7D). Some authors have, however, reported decreased 410 
dissolution with amorphous solid dispersions with high PVP-IND ratios when compared to a 411 
formulations with low PVP-IND ratio [69,70]. This phenomenon was attributed to increased 412 
viscosity, which may have also reduced the IND release in the present study. With the B 413 
formulations, the amount of IBU-ARG had no significant effect on the CDA15min, probably due to 414 
the incomplete drug release. According to the model, an increase in the amount of PVP, however, 415 
significantly increased the CDA15min of the B formulations suggesting the positive effect of PVP on 416 
IBU release, which has been reported previously [71].   417 
The drug release from formulations containing co-amorphous mixtures was faster than from 418 
formulations containing physical drug-ARG mixture or plain crystalline drug, even though ARG in 419 
the physical mixtures also enhanced drug release (Figure 7A and B). Additionally, with the N2-420 
formulation, the presence of ARG and the formation of an amorphous system significantly 421 
increased the cumulative dissolved amount of IND at the end of the dissolution study (7.7%, 57.0% 422 
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and 92.7% drug release from tablets containing plain IND, physical IND-ARG mixture and co-423 
amorphous IND-ARG salt, respectively). The drug release was highest also from the B2 424 
formulation containing co-amorphous IBU-ARG (45.2%), but there was no significant difference in 425 
the amount of released drug between tablets containing physical mixture or crystalline IBU (31.9% 426 
and 25.5%, respectively). The enhanced IBU and IND dissolution upon formation of the co-427 
amorphous system has been attributed to both its amorphous nature as well as salt formation 428 
between the acidic drug and basic ARG [11,16,19,72]. With IND-ARG, enhanced drug release also 429 
from the tablet formulation has been observed previously [21]. However, in our previous study [19], 430 
the IND-ARG physical mixture (crystalline components) and γ-IND seemed to result in similar 431 
dissolution profiles, whereas in the present study, drug release was higher with the physical 432 
mixture. This may be due to the in situ amorphization of IND-ARG, which has been previously 433 
observed to occur in tablets containing an IND-ARG physical mixture [21,22]. Lenz et al. [21] 434 
observed a colour change from white to yellow when tablets containing physical IND-ARG were 435 
immersed in the dissolution medium as well as a clear supersaturation followed by a rapid decrease 436 
in IND concentration (recrystallization). In the present study, the colour change could also be 437 
observed, but the PVP added to the tablet formulation possibly inhibited drug precipitation from 438 
supersaturated solution. 439 
Based on the dissolution profiles from the 24h dissolution study (Figure 7C), the cumulative 440 
dissolved amount of IBU from the B4-formulation containing PVP remained relatively constant 441 
(~34 mg or 45%) between 15min and 24h, whereas with the tablets lacking PVP only ~11 mg 442 
(15%) was released after 15 min of dissolution. However, the release of IBU from tablets without 443 
PVP continued throughout the study, and at 24h, the difference in cumulative dissolved amounts 444 
between tablets containing and lacking PVP was no longer significant. With the N2-formulation 445 
(Figure 7D), the IND release from both tablets (with and without PVP) was relatively fast (~69 mg 446 
(92%) after 15 min). However, with the formulation without PVP, the dissolved amount of IND 447 
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began to decrease already after 15 min, and from 2h onwards it was significantly lower than with 448 
the formulation containing PVP. The cumulative dissolved IND from the N2-formulation 449 
containing PVP decreased only slightly during the 24h. These observations clearly indicated the 450 
solubilizing and precipitation inhibitory effects of PVP. With IND the precipitation inhibitory effect 451 
of PVP has been attributed to crystal growth inhibition caused by adsorption of PVP on IND 452 
surfaces, whereas with IBU the solubilization is due to the strong interactions between IBU and 453 
PVP [67,73-82].  454 
It has also been relatively unknown, if the co-amorphous formulations maintain their dissolution 455 
advantage over for example PM or amorphous drug alone, when formulated as tablets [10]. 456 
However, based on the present study, even a relatively small addition of stabilizing polymer as a 457 
physical mixture with co-amorphous powder might stabilize the supersaturation of the amorphous 458 
drug. A similar observation was made by Petry et al. [22] by coating tablets containing co-459 
amorphous IND-ARG with a polymeric coating. However, even though the film coating was 460 
applied to protect the formulation from moisture, the coating process itself causes various stresses 461 
(heat, moisture, mechanical) to the formulation. Thus, incorporating the polymer to the tablet 462 
formulation, as shown in the present work, might be suitable also for materials that cannot 463 
withstand a coating process. 464 
3.2.3 Tablet characterization 465 
The stability studies were conducted with every formulation (B1-B9 and N1-N9), but since the 466 
observations from the formulations containing the same drug-ARG mixture and sugar alcohol 467 
resembled each other, the X-ray diffractograms and FTIR spectra of B2-, B4-, N2- and N6-468 
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formulation are shown here as examples (Figure 8). The diffractograms and spectra of other 469 
formulations can be found from the supplementary material (Figures S5 and S6). 470 
At day 0, the majority of the diffractograms showed only peaks originating from either mannitol or 471 
xylitol (Figure 8A and Figures S5 and S6), which indicates that despite the possible mechanical and 472 
heat stresses [24,25], the co-amorphous salts were physically stable under compaction. 473 
Additionally, no signs of recrystallization could be observed during the 20-week stability study in 474 
the diffractograms of either the IBU-ARG formulations containing mannitol or any of the N 475 
formulations. IND-ARG has been found to be highly stable under various conditions and as a pure 476 
powder or when formulated as tablets [11,16,19,21,22]. Additionally, in our previous study [19], 477 
co-amorphous IBU-ARG did not recrystallize over one year in dry conditions, but at 60% RH 478 
liquefaction occurred. In the present study, the tablets retained their original appearance, and in the 479 
tablets containing mannitol, the IBU-ARG mixture remained amorphous. However, already at day 480 
0, the diffractogram of B1-formulation included a small peak appeared at approximately 16.8° (2θ), 481 
which could be observed in the diffractograms of every formulation containing IBU-ARG and 482 
xylitol after 6 weeks. Additionally, a peak at approximately 19.0 ° (2θ) emerged in almost every 483 
diffractogram of these formulations. In the diffractograms from 12- and 20-week time points, these 484 
peaks became more obvious, and a peak at approximately 6.0° (2θ) began to appear.  485 
The IR spectra between 1400-1800 cm-1 of all the N-formulations and the spectra of mannitol 486 
containing B-formulations corresponded to the spectra reported previously [16,19,21,72], and 487 
remained unchanged during the 20 week stability study indicating salt formation between the 488 
components as well as high physical stability (Figures 8B and S6). However, with B-formulations 489 
containing xylitol, peak shifted and new peaks appeared (Figures 8B and S5). Instead of the broad 490 
CN stretch band at 1540 cm-1 in the spectrum of co-amorphous IBU-ARG salt, a peak with two 491 
maxima at 1566 and 1577 cm-1 appeared in the spectra of the stored B1-, B2-, B5-, B6- and B9-492 
formulations. These peaks may originate from the antisymmetric stretch of the ionized carboxylic 493 
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acid group of IBU as well as from the shifted CN-stretching vibration of ARG [72]. Additionally, 494 
the peak at 1632 cm-1 (ARG guanidyl group stretching) and the shoulder at 1668 cm-1 (ARG COO- 495 
and guanidyl group stretching) in the IBU-ARG spectrum had shifted to a peak at 1629 cm-1 and to 496 
a shoulder at 1657 cm-1, respectively, and a new shoulder appeared at 1704 cm-1 (IBU carbonyl 497 
stretching). With B1-, B2-, B6- and B9-formulations, these changes occurred already after 6 weeks 498 
of storage, and after 20 weeks they were present also in the spectrum of the B5-formulation 499 
(samples were not measured at 12 weeks).  500 
The peaks appearing in the diffractograms of the B formulations containing xylitol could be 501 
attributed to either crystalline IBU (peaks at 6.1°, 16.6°, 16.7° and 19.0° (2θ)) or ARG (peaks at 502 
16.8° and 19.1° (2θ)) (diffractograms not shown), but the components may also have crystallized as 503 
a salt, as observed by Kasten et al. [83] with IND-lysine. Additionally, Petry et al. [84] observed the 504 
formation of a crystalline IND-ARG salt after storing the IND-ARG physical mixture under 75% 505 
RH. However, since we have been unable to produce crystalline IBU-ARG [19], no reference 506 
diffractogram of crystalline IBU-ARG salt was available. The appearance of a shoulder at 1704 cm-507 
1 in the IR spectra of these formulations suggest that IBU had, at least partly, recrystallized as a free 508 
acid. However, due to the other spectral changes, also the crystalline IBU-ARG salt may be present 509 
in the xylitol containing IBU-ARG formulations. The presence of PVP complicates the analysis 510 
further, since it interacts strongly with IBU and even solid-state in situ amorphization has been 511 
observed [73,85,86]. Thus, the exact nature of the recrystallized species could not be resolved with 512 
the current methods, and the coexistence of amorphous IBU-ARG together with crystalline IBU 513 
and/or ARG and/or IBU-ARG salt seemed possible. However, xylitol reduced the physical stability 514 
of co-amorphous IBU-ARG, possibly due to its higher hygroscopicity when compared to mannitol 515 
[51]. 516 
Multimodal non-linear optical imaging, specifically involving CARS and SFG/SHG, was used to 517 
visualize the tablet surfaces over the 20 week period. Crystalline arginine, xylitol and mannitol 518 
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exhibited strong SFG/SHG signals due to their non-centrosymmetric crystal structures. L-arginine 519 
has a monoclinic crystal structure with space group P21 (CSD code TAQBIY [87]) and xylitol and 520 
D-mannitol have orthorhombic crystal structures with space group P212121  (CSD codes 521 
XYLTOL04 [88] for xylitol and DMANTL08 [89] and DMANTL09 [90] for the alpha and beta 522 
polymorphs of D-mannitol, respectively) [91-93]. The spray-dried co-amorphous mixtures and 523 
centrosymmetric crystalline ibuprofen and gamma indomethacin did not exhibit SFG/SHG signals 524 
(data not shown). Gamma indomethacin has a triclinic structure with space group P1̅ (CSD code 525 
INDMET03 [94]) and ibuprofen has a monoclinic structure with space group P21/c (CSD code 526 
IBPRAC06 [95]) [96,97].The SFG/SHG activities of amorphous, gamma and alpha indomethacin, 527 
their Raman and CARS spectra as well as the tendency of indomethacin to recrystallize to the 528 
gamma-form under relatively dry conditions are known [35].  529 
The CARS and Raman spectra of the co-amorphous IND-ARG mixture exhibited similarities to the 530 
spectra of amorphous indomethacin with two distinguishable C=O stretching peaks at 1579 cm-1 531 
and 1676 cm-1 (Figure S7 A and B) [35,98]. Crystalline ibuprofen exhibited a distinguishable 532 
CARS peak at 1603 cm-1 (Figure S7 B). This C-C stretching peak [99] typically moves to higher 533 
Raman shifts when the ibuprofen is amorphous, for example in an amorphous solid dispersion with 534 
PVP [100]. The CARS spectra of the co-amorphous mixture of IBU-ARG revealed this shift with 535 
the peak at 1615 cm-1 (Figure S7 B and C). PVP exhibited its broad amide C=O stretching peak at 536 
around 1640 – 1676 cm-1 (Figure S7 A and B) [101]. Xylitol and mannitol exhibited a CH2 537 
stretching peak at 1472 cm-1 and 1460 cm-1 in the CARS spectra, respectively [102] (Figure S7 A 538 
and B). The CARS spectrum of arginine lacked any distinguishable peaks (Figure S7 A and B).  539 
On the basis of these analyses, the distribution of different chemical components on tablet surfaces 540 
could be imaged by combining CARS and SFG/SHG microscopies. Xylitol and mannitol could be 541 
probed by SFG/SHG, while amorphous IND-ARG, IBU-ARG and PVP could be imaged using 542 
CARS (Figure 9 and S9-13). In the images some regions appear darker than others due the surface 543 
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roughness of the tablets (the non-linear optical signal is generated only at the small focal point). 544 
Since CARS spectra were measured on tablet surfaces, it was possible to use different approaches to 545 
form images and extracted spectra from different regions could be further used to identify different 546 
chemical and solid-state components spatially. A PCA based approach was successfully used to 547 
visualize component distribution on the IBU-ARG tablet surfaces (formulations B2 and B4, Figure 548 
9 A,D,G,I). However, the indomethacin signal from IND-ARG tablets was so dominant that a PCA 549 
based approach was not able to identify PVP (data not shown). However, PVP could be 550 
distinguished by visualizing the tablet surface using a single CARS shift at 1652 cm-1 (C=O 551 
stretching specific to PVP) with supportive spectral information extracted from regions of interest 552 
confirming the spectral profile of PVP (Figure S9). On the other hand spectral differences between 553 
the PVP and drug-ARG mixtures could be utilized in fast narrowband single-shift CARS imaging, 554 
together with simultaneous SFG/SHG imaging, as demonstrated in tile scan obtained from the IBU-555 
ARG formulation B2 (Figure S10).  556 
The CARS and SEM images (Figure 9 and Figures S9-S12 and S14) suggest that the spray dried 557 
particles were much more prominent on the surfaces of the freshly prepared tablets than could be 558 
expected based on the high mass percentage of mannitol or xylitol. Additionally, the CARS images 559 
indicated that the spray-dried particles were considerably smaller than the PVP and sugar alcohol 560 
particles, and that the sugar alcohol particles as well as PVP particles were surrounded by the spray 561 
dried particles. Barra et al. [103] reported the adherence of small excipient particles with preferable 562 
compaction properties on larger poorly compacting drug particles, which resulted in enhanced 563 
compaction properties of the mixture when compared to mixtures where no interactions existed 564 
between the drug end excipient particles. Thus, the observations on component distribution based 565 
on CARS images might have indicated a significant effect of the amount of drug-ARG mixtures on 566 
the compaction properties of the powders as well as on the mechanical properties of the tablets. 567 
However, the models predicting compaction and tablet properties suggested that the sugar alcohol 568 
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species was the most significant factor affecting the investigated responses and only with elastic 569 
recovery, the model prediction could possibly be explained by the visual observations (i.e. coverage 570 
of the sugar alcohol particles by the spray-dried particles). This discrepancy between model 571 
predictions and visual observations may be explained by the small changes in the amounts of drug-572 
ARG mixtures when compared to the change of the entire sugar alcohol species. Thus, in the future, 573 
it would be beneficial to perform compaction studies with larger variation in the amount of the 574 
spray-dried material in order to verify the significance of the co-amorphous material on the 575 
compaction process suggested by the CARS and SEM. 576 
The most prominent difference between CARS/SFG/SHG images of IBU-ARG and IND-ARG 577 
obtained over the 20 week period was the change in surface morphology, which was confirmed by 578 
the SEM images from fresh and stored (6 months) tablets (Figures S11, S12 and S14). On day 0, the 579 
co-amorphous drug-ARG particles could be clearly seen in both B- and N- formulations. However, 580 
the surface of IBU-ARG tablets (B4- and B2- formulations) became smoother and individual 581 
particles were not visible anymore. This change in surface morphology could be observed already 582 
on week 4 (Figure S13) and smooth surface appearance remained over 20 week period (Figure 9). 583 
However, CARS spectroscopy revealed that spectra extracted from tablet surfaces on day 0 and on 584 
week 20 resembled closely each other in IBU-ARG formulations B4 and B2 (Figure 9) and IND-585 
ARG formulations N2 and N6 (Figure S9), thus any recrystallization in both IBU-ARG and IND-586 
ARG tablets was not observed with the non-linear optical imaging.  587 
Since signs of recrystallization were observed in the B2 formulation with XRD and FTIR already 588 
after 6 weeks of storage, these techniques were also used to measure the tablets imaged with CARS 589 
after 14 and 20 weeks of storage (data not shown). After 14 weeks no crystallization was observed 590 
with any of the formulations, but after 20 weeks a small peak at 16.9° 2θ appeared in the 591 
diffractogram of B2 formulation and minor changes could also be observed in its IR spectrum. The 592 
higher stability of the B2 formulation imaged with CARS when compared to the one examined with 593 
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XRD and FTIR may be due to the moisture absorption of the spray dried powder prior to the 594 
compression, which was more pronounced during the preparation of the tablets for XRD and FTIR 595 
than for the non-linear optical imaging. However, since recrystallization could also be detected with 596 
XRD and FTIR in the B2 formulation imaged with CARS, it seems that the crystallisation was 597 
limited and occurred outside the limited surface area (465x465 µm) probed with non-linear optical 598 
imaging. Detection of recrystallization with CARS may also have been compromised by the lack of 599 
reference IBU-ARG crystalline salt, although it is likely that the crystalline salt would have 600 
exhibited some CARS spectral and/or SFG signal differences compared to the amorphous form.  601 
One main benefit of coherent Raman imaging such as CARS with SFG/SHG microscopy is the 602 
imaging speed. Tile scan shown in Figure S10 was composed of 20 1024 × 1024 pixel images 603 
acquired at two CARS shifts 1652 cm-1 (PVP) and 1615 cm-1 (IBU-ARG) with a pixel dwell time of 604 
1.2 µs resulting in a total acquisition without laser tuning of approximately 1 min. Additionally, 605 
data-acquisition time in spectral scan was approximately 15 min, whereas it can take up to hours to 606 
perform spontaneous Raman mapping [104]. In the present study, it was shown that non-linear 607 
optical imaging is well-suited to stability analysis of formulated tablet surfaces. Nevertheless, 608 
confirming and thus imaging the chemical- and solid-state forms of different species requires non-609 
linear optical knowledge of the crystallizing species and proper reference materials. 610 
4. Conclusions 611 
In the present study, tablets of sufficient strength could be produced from both co-amorphous IBU-612 
ARG and IND-ARG salts, which also were found to be relatively physically stable during tablet 613 
compaction, even though this may be affected by the excipients. However, based on the results of 614 
the experimental design, mannitol could be recommended as a diluent for co-amorphous 615 
formulations over xylitol, since mannitol produced stronger tablets with no recrystallization in any 616 
of the formulations, whereas XRD and FTIR detected signs of recrystallization from tablets 617 
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containing IBU-ARG and xylitol. The drug release was more efficient from the tablets containing 618 
co-amorphous mixtures when compared to physical mixtures, and a small amount of PVP added to 619 
the formulation as a physical mixture was found to be effective in preventing drug recrystallisation 620 
from supersaturated solutions, which might be useful with physically stable co-amorphous mixtures 621 
that may be unable to stabilize supersaturation.  In the present study, synergistic and simultaneous 622 
CARS/SFG/SHG imaging/spectroscopy was successfully used to map different chemical 623 
components on tablet surfaces. We were unable to detect phase separation or recrystallization of the 624 
co-amorphous components due to their high physical stability. Thus, due to the capability of high 625 
speed imaging of tablet surfaces, CARS and SFG/SHG are interesting options to complement the 626 
traditional XRD and FTIR in physical stability monitoring. 627 
ACKNOWLEDGMENTS 628 
The authors thank Microscopy laboratory at SIB Labs, University of Eastern Finland for providing 629 
laboratory facilities, PhD Jari Leskinen for SEM imaging and Master student Jarmo Maaranen for 630 
his skilful technical assistance. RO acknowledges the support from the Doctoral Programme in 631 
Drug Research in the Doctoral School of University of Eastern Finland as well as Nordforsk 632 
(NordicPOP, project number 85352). JS and CS acknowledge the Academy of Finland (project 633 
number 289398) and Business Finland (project number 462073). 634 
APPENDIX 635 
Supplementary data associated with this article can be found in the online version. 636 
 637 
  638 
28 
 
REFERENCES 639 
[1] H.D. Williams, N.L. Trevaskis, S.A. Charman, R.M. Shanker, W.N. Charman, C.W. Pouton, 640 
C.J. Porter, Strategies to address low drug solubility in discovery and development, Pharmacol. 641 
Rev. 65 (2013) 315-499. doi: 10.1124/pr.112.005660.  642 
[2] M. Rodriguez-Aller, D. Guillarme, J. Veuthey, R. Gurny, Strategies for formulating and 643 
delivering poorly water-soluble drugs, J. Drug Deliv. Sci. Technol. 30 (2015) 342-351. doi: 644 
10.1016/j.jddst.2015.05.009. 645 
[3] B.C. Hancock, G. Zografi, Characteristics and Significance of the Amorphous State in 646 
Pharmaceutical Systems, J. Pharm. Sci. 86 (1997) 1-12. doi: 10.1021/js9601896 647 
[4] R. Laitinen, K. Löbmann, C.J. Strachan, H. Grohganz, T. Rades, Emerging trends in the 648 
stabilization of amorphous drugs, Int. J. Pharm. 453 (2013) 65-79. doi: 649 
10.1016/j.ijpharm.2012.04.066. 650 
[5] P. Kanaujia, P. Poovizhi, W.K. Ng, R.B.H. Tan, Amorphous formulations for dissolution and 651 
bioavailability enhancement of poorly soluble APIs, Powder Technol. 285 (2015) 2-15. doi: 652 
10.1016/j.powtec.2015.05.012. 653 
[6] K.K. Qian, R.H. Bogner, Application of mesoporous silicon dioxide and silicate in oral 654 
amorphous drug delivery systems, J. Pharm. Sci. 101 (2012) 444-463. doi: 10.1002/jps.22779. 655 
[7] H. Grohganz, P.A. Priemel, K. Löbmann, L.H. Nielsen, R. Laitinen, A. Mullertz, G. Van den 656 
Mooter, T. Rades, Refining stability and dissolution rate of amorphous drug formulations, Expert 657 
Opin. Drug Deliv. 11 (2014) 977-989. doi: 10.1517/17425247.2014.911728. 658 
[8] S. Baghel, H. Cathcart, N.J. O'Reilly, Polymeric Amorphous Solid Dispersions: A Review of 659 
Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous 660 
Solubilization of Biopharmaceutical Classification System Class II Drugs, J. Pharm. Sci. 105 661 
(2016) 2527-2544. doi: 10.1016/j.xphs.2015.10.008. 662 
[9] S.J. Dengale, H. Grohganz, T. Rades, K. Löbmann, Recent advances in co-amorphous drug 663 
formulations, Adv. Drug Deliv. Rev. 100 (2016) 116-125. doi: 10.1016/j.addr.2015.12.009. 664 
[10] R. Laitinen, K. Löbmann, H. Grohganz, P. Priemel, C.J. Strachan, T. Rades, Supersaturating 665 
drug delivery systems: The potential of co-amorphous drug formulations, Int. J. Pharm. 532 (2017) 666 
1-12. doi: 10.1016/j.ijpharm.2017.08.123. 667 
[11] K. Löbmann, H. Grohganz, R. Laitinen, C. Strachan, T. Rades, Amino acids as co-amorphous 668 
stabilizers for poorly water soluble drugs-Part 1: preparation, stability and dissolution enhancement, 669 
Eur. J. Pharm. Biopharm. 85 (2013) 873-881. doi: 10.1016/j.ejpb.2013.03.014. 670 
[12] R. Ojarinta, A.T. Heikkinen, E. Sievänen, R. Laitinen, Dissolution behavior of co-amorphous 671 
amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state 672 
of indomethacin, Eur. J. Pharm. Biopharm. 112 (2017) 85-95. doi: 10.1016/j.ejpb.2016.11.023. 673 
29 
 
[13] W. Wu, K. Löbmann, T. Rades, H. Grohganz, On the role of salt formation and structural 674 
similarity of co-formers in co-amorphous drug delivery systems, Int. J. Pharm. 535 (2018) 86-94. 675 
doi: 10.1016/j.ijpharm.2017.10.057. 676 
[14] G. Craye, K. Löbmann, H. Grohganz, T. Rades, R. Laitinen, Characterization of Amorphous 677 
and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying, Molecules 20 (2015) 678 
21532-21548. doi: 10.3390/molecules201219784. 679 
[15] A. Beyer, L. Radi, H. Grohganz, K. Löbmann, T. Rades, C.S. Leopold, Preparation and 680 
recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin, Eur. J. Pharm. 681 
Biopharm. 104 (2016) 72-81. doi: 10.1016/j.ejpb.2016.04.019. 682 
[16] K.T. Jensen, L.I. Blaabjerg, E. Lenz, A. Bohr, H. Grohganz, P. Kleinebudde, T. Rades, K. 683 
Löbmann, Preparation and characterization of spray-dried co-amorphous drug-amino acid salts, J. 684 
Pharm. Pharmacol. 68 (2016) 615-624. doi: 10.1111/jphp.12458. 685 
[17] L. Arnfast, M. Kamruzzaman, K. Löbmann, J. Aho, S. Baldursdottir, T. Rades, J. Rantanen, 686 
Melt Extrusion of High-Dose Co-Amorphous Drug-Drug Combinations, Pharm. Res. (2017) 1-9. 687 
doi: 10.1007/s11095-017-2254-8. 688 
[18] E. Lenz, K. Löbmann, T. Rades, K. Knop, P. Kleinebudde, Hot Melt Extrusion and Spray 689 
Drying of Co-amorphous Indomethacin-Arginine With Polymers, J. Pharm. Sci. 106 (2017) 302-690 
312. doi: 10.1016/j.xphs.2016.09.027. 691 
[19] R. Ojarinta, L. Lerminiaux, R. Laitinen, Spray drying of poorly soluble drugs from aqueous 692 
arginine solution, Int. J. Pharm. 532 (2017) 289-298. doi: 10.1016/j.ijpharm.2017.09.015. 693 
[20] R.B. Chavan, R. Thipparaboina, D. Kumar, N.R. Shastri, Co amorphous systems: A product 694 
development perspective, Int. J. Pharm. 515 (2016) 403-415. doi: 10.1016/j.ijpharm.2016.10.043. 695 
[21] E. Lenz, K.T. Jensen, L.I. Blaabjerg, K. Knop, H. Grohganz, K. Löbmann, T. Rades, P. 696 
Kleinebudde, Solid-state properties and dissolution behaviour of tablets containing co-amorphous 697 
indomethacin-arginine, Eur. J. Pharm. Biopharm. 96 (2015) 44-52. doi: 10.1016/j.ejpb.2015.07.011. 698 
[22] I. Petry, K. Löbmann, H. Grohganz, T. Rades, C.S. Leopold, Solid state properties and drug 699 
release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect, 700 
Eur. J. Pharm. Biopharm. 119 (2017) 150-160. doi: 10.1016/j.ejpb.2017.06.007. 701 
[23] Renuka, S.K. Singh, M. Gulati, R. Narang, Stable amorphous binary systems of glipizide and 702 
atorvastatin powders with enhanced dissolution profiles: formulation and characterization, Pharm. 703 
Dev. Technol. 22 (2017) 13-25. doi: 10.3109/10837450.2015.1125921. 704 
[24] S. Patel, A.M. Kaushal, A.K. Bansal, Compression physics in the formulation development of 705 
tablets, Crit. Rev. Ther. Drug Carrier Syst. 23 (2006) 1-65. doi: 706 
10.1615/CritRevTherDrugCarrierSyst.v23.i1.10 707 
[25] B. Demuth, Z.K. Nagy, A. Balogh, T. Vigh, G. Marosi, G. Verreck, I. Van Assche, M.E. 708 
Brewster, Downstream processing of polymer-based amorphous solid dispersions to generate tablet 709 
formulations, Int. J. Pharm. 486 (2015) 268-286. doi: 10.1016/j.ijpharm.2015.03.053. 710 
30 
 
[26] A. Agrawal, M. Dudhedia, W. Deng, K. Shepard, L. Zhong, E. Povilaitis, E. Zimny, 711 
Development of Tablet Formulation of Amorphous Solid Dispersions Prepared by Hot Melt 712 
Extrusion Using Quality by Design Approach, AAPS PharmSciTech 17 (2016) 214-232. doi: 713 
10.1208/s12249-015-0472-0. 714 
[27] P.T. Mah, D. Novakovic, J. Saarinen, S. Van Landeghem, L. Peltonen, T. Laaksonen, A. 715 
Isomäki, C.J. Strachan, Elucidation of Compression-Induced Surface Crystallization in Amorphous 716 
Tablets Using Sum Frequency Generation (SFG) Microscopy, Pharm. Res. 34 (2017) 957-970. doi: 717 
10.1007/s11095-016-2046-6. 718 
[28] N.K. Thakral, S. Mohapatra, G.A. Stephenson, R. Suryanarayanan, Compression-induced 719 
crystallization of amorphous indomethacin in tablets: Characterization of spatial heterogeneity by 720 
two-dimensional X-ray diffractometry, Mol. Pharm. 12 (2015) 253-263. doi: 10.1021/mp5005788. 721 
[29] C.J. Strachan, M. Windbergs, H.L. Offerhaus, Pharmaceutical applications of non-linear 722 
imaging, Int. J. Pharm. 417 (2011) 163-172. doi: 10.1016/j.ijpharm.2010.12.017. 723 
[30] J.X. Cheng, X.S. Xie, Coherent anti-Stokes Raman scattering microscopy: Instrumentation, 724 
theory, and applications, J. Phys. Chem. B 108 (2004) 827-840. doi: 10.1021/jp035693v 725 
[31] P.J. Campagnola, A.C. Millard, M. Terasaki, P.E. Hoppe, C.J. Malone, W.A. Mohler, Three-726 
dimensional high-resolution second-harmonic generation imaging of endogenous structural proteins 727 
in biological tissues, Biophys. J. 82 (2002) 493-508. doi: 10.1016/S0006-3495(02)75414-3. 728 
[32] J.X. Cheng, X.S. Xie, Vibrational spectroscopic imaging of living systems: An emerging 729 
platform for biology and medicine, Science 350 (2015) doi: 10.1126/science.aaa8870. 730 
[33] J. Pirhonen, J. Arola, S. Sädevirta, P. Luukkonen, S. Karppinen, T. Pihlajaniemi, A. Isomäki, 731 
M. Hukkanen, H. Yki-Järvinen, E. Ikonen, Continuous Grading of Early Fibrosis in NAFLD Using 732 
Label-Free Imaging: A Proof-of-Concept Study, PLoS One 11 (2016) e0147804. doi: 733 
10.1371/journal.pone.0147804. 734 
[34] C.M. Hartshorn, Y.J. Lee, C.H. Camp, Z. Liu, J. Heddleston, N. Canfield, T.A. Rhodes, A.R. 735 
Hight Walker, P.J. Marsac, M.T. Cicerone, Multicomponent chemical imaging of pharmaceutical 736 
solid dosage forms with broadband CARS microscopy, Anal. Chem. 85 (2013) 8102-8111. doi: 737 
10.1021/ac400671p. 738 
[35] D. Novakovic, J. Saarinen, T. Rojalin, O. Antikainen, S.J. Fraser-Miller, T. Laaksonen, L. 739 
Peltonen, A. Isomäki, C.J. Strachan, Multimodal Nonlinear Optical Imaging for Sensitive Detection 740 
of Multiple Pharmaceutical Solid-State Forms and Surface Transformations, Anal. Chem. 89 (2017) 741 
11460-11467. doi: 10.1021/acs.analchem.7b02639. 742 
[36] A. Fussell, E. Garbacik, H. Offerhaus, P. Kleinebudde, C. Strachan, In situ dissolution analysis 743 
using coherent anti-Stokes Raman scattering (CARS) and hyperspectral CARS microscopy, Eur. J. 744 
Pharm. Biopharm. 85 (2013) 1141-1147. doi: 10.1016/j.ejpb.2013.08.012. 745 
[37] C.J. Strachan, T. Rades, C.J. Lee, Determination of the optical second harmonic response of 746 
pharmaceutical solid-solid mixtures, Opt. Lasers Eng. 43 (2005) 209-220. doi: 747 
10.1016/j.optlaseng.2004.06.004. 748 
31 
 
[38] D. Wanapun, U.S. Kestur, L.S. Taylor, G.J. Simpson, Single Particle Nonlinear Optical 749 
Imaging of Trace Crystallinity in an Organic Powder, Anal. Chem. 83 (2011) 4745-4751. doi: 750 
10.1021/ac1031397. 751 
[39] J.C. Parajó, H. Domínguez, J.M. Domínguez, Biotechnological production of xylitol. Part 1: 752 
Interest of xylitol and fundamentals of its biosynthesis, Bioresour. Technol. 65 (1998) 191-201. doi: 753 
10.1016/S0960-8524(98)00038-8. 754 
[40] J. Hellrup, J. Nordström, D. Mahlin, Powder compression mechanics of spray-dried lactose 755 
nanocomposites, Int. J. Pharm. 518 (2017) 1-10. doi: 10.1016/j.ijpharm.2016.12.041. 756 
[41] R.C. Rowe, P.J. Sheskey, C. Owen Siân (Eds.), Handbook of Pharmaceutical Excipients, 5th 757 
ed., Pharmaceutical Press and American Pharmacists Association, London, 2006. 758 
[42] X. Cao, N. Leyva, S.R. Anderson, B.C. Hancock, Use of prediction methods to estimate true 759 
density of active pharmaceutical ingredients, Int. J. Pharm. 355 (2008) 231-237. doi: 760 
10.1016/j.ijpharm.2007.12.012. 761 
[43] E. Berlin, M.J. Pallansch, Densities of several proteins and L-amino acids in the dry state. J. 762 
Phys. Chem. 72 (1968) 1887-1889. doi: 10.1021/j100852a004 763 
[44] M. Kuentz, H. Leuenberger, Pressure susceptibility of polymer tablets as a critical property: A 764 
modified Heckel equation, J. Pharm. Sci. 88 (1999) 174-179. doi: 10.1021/js980369a. 765 
[45] S. Paul, C.C. Sun, The suitability of common compressibility equations for characterizing 766 
plasticity of diverse powders, Int. J. Pharm. 532 (2017) 124-130. doi: 767 
10.1016/j.ijpharm.2017.08.096. 768 
[46] N.A. Armstrong, R.F. Haines-Nutt, Elastic recovery and surface area changes in compacted 769 
powder systems, Powder Technol. 9 (1974) 287-290. doi: 10.1016/0032-5910(74)80054-9. 770 
[47] J.T. Fell, J.M. Newton, Determination of Tablet Strength by the Diametral-Compression Test, 771 
J. Pharm. Sci. 59 (1970) 688-691. doi: 10.1002/jps.2600590523 772 
[48] N. Willecke, A. Szepes, M. Wunderlich, J.P. Remon, C. Vervaet, T. De Beer, A novel 773 
approach to support formulation design on twin screw wet granulation technology: Understanding 774 
the impact of overarching excipient properties on drug product quality attributes, Int. J. Pharm. 545 775 
(2018) 128-143. doi: 10.1016/j.ijpharm.2018.04.017. 776 
[49] MODDE 11 User Guide, MKS Umetrics AB, Sweden 777 
[50] R. Vehring, Pharmaceutical particle engineering via spray drying, Pharm. Res. 25 (2008) 999-778 
1022. doi: 10.1007/s11095-007-9475-1.  779 
[51] G.K. Bolhuis, E.G. Rexwinkel, K. Zuurman, Polyols as filler-binders for disintegrating tablets 780 
prepared by direct compaction, Drug Dev. Ind. Pharm. 35 (2009) 671-677. doi: 781 
10.1080/03639040802587799. 782 
32 
 
[52] T. Tanner, O. Antikainen, H. Ehlers, D. Blanco, J. Yliruusi, Examining mechanical properties 783 
of various pharmaceutical excipients with the gravitation-based high-velocity compaction analysis 784 
method, Int. J. Pharm. 539 (2018) 131-138. doi: 10.1016/j.ijpharm.2018.01.048 785 
[53] P.V. Marshall, P. York, J.Q. Maclaine, An investigation of the effect of the punch velocity on 786 
the compaction properties of ibuprofen, Powder Technol. 74 (1993) 171-177. doi: 10.1016/0032-787 
5910(93)87009-D. 788 
[54] L.E. Morris, J.C. Moore, J.B. Schwartz, Characterization and performance of a new direct 789 
compression excipient for chewable tablets: Xylitab®, Drug Dev. Ind. Pharm. 22 (1996) 925-932. 790 
doi: 10.3109/03639049609065922. 791 
[55] P. Di Martino, M. Beccerica, E. Joiris, G.F. Palmieri, A. Gayot, S. Martelli, Influence of 792 
crystal habit on the compression and densification mechanism of ibuprofen, J. Cryst. Growth 243 793 
(2002) 345-355. doi: 10.1016/S0022-0248(02)01523-3. 794 
[56] V. Mazel, V. Busignies, H. Diarra, P. Tchoreloff, On the links between elastic constants and 795 
effective elastic behavior of pharmaceutical compacts: Importance of poisson's ratio and use of bulk 796 
modulus, J. Pharm. Sci. 102 (2013) 4009-4014. doi: 10.1002/jps.23710. 797 
[57] A. Nokhodchi, J.L. Ford, P.H. Rowe, M.H. Rubinstein, The effects of compression rate and 798 
force on the compaction properties of different viscosity grades of hydroxypropylmethylcellulose 799 
2208, Int. J. Pharm. 129 (1996) 21-31. doi: 10.1016/0378-5173(95)04236-9. 800 
[58] O.F. Akande, M.H. Rubinstein, P.H. Rowe, J.L. Ford, Effect of compression speeds on the 801 
compaction properties of a 1:1 paracetamol-microcrystalline cellulose mixture prepared by single 802 
compression and by combinations of pre-compression and main-compression, Int. J. Pharm. 157 803 
(1997) 127-136. doi: 10.1016/S0378-5173(97)00185-3. 804 
[59] H. Larhrib, J.I. Wells, M.H. Rubinstein, Compressing polyethylene glycols: The effect of 805 
compression pressure and speed, Int. J. Pharm. 147 (1997) 199-205. doi: 10.1016/S0378-806 
5173(96)04818-1. 807 
[60] J. Ruangchayajatuporn, T. Amornsakchai, N. Sinchaipanid, A. Mitrevej, Compaction behavior 808 
and optimization of spray-dried lactose with various amorphous content, J. Drug Deliv. Sci. 809 
Technol. 21 (2011) 175-181. doi: 10.1016/S1773-2247(11)50019-X. 810 
[61] N. Al-Zoubi, F. Odeh, I. Nikolakakis, Co-spray drying of metformin hydrochloride with 811 
polymers to improve compaction behavior, Powder Technol. 307 (2017) 163-174. doi: 812 
10.1016/j.powtec.2016.11.027 813 
[62] T. Suzuki, H. Nakagami, Effect of crystallinity of microcrystalline cellulose on the 814 
compactability and dissolution of tablets, Eur. J. Pharm. Biopharm. 47 (1999) 225-230. doi: 815 
10.1016/S0939-6411(98)00102-7. 816 
[63] A.R. Paradkar, B. Chauhan, S. Yamamura, A.P. Pawar, Preparation and characterization of 817 
glassy celecoxib, Drug Dev. Ind. Pharm. 29 (2003) 739-744. doi: 10.1081/DDC-120021773. 818 
[64] A.B. Joshi, S. Patel, A.M. Kaushal, A.K. Bansal, Compaction studies of alternate solid forms 819 
of celecoxib, Adv. Powder Technol. 21 (2010) 452-460. doi: 10.1016/j.apt.2010.01.006. 820 
33 
 
[65] J. Rojas, S. Hernandez, Effect of the compaction platform on the densification parameters of 821 
tableting excipients with different deformation mechanisms, Chem. Pharm. Bull. 62 (2014) 281-822 
287. doi: 10.1248/cpb.c13-00884. 823 
[66] A. Forster, J. Hempenstall, T. Rades, Characterization of glass solutions of poorly water-824 
soluble drugs produced by melt extrusion with hydrophilic amorphous polymers, J. Pharm. 825 
Pharmacol. 53 (2001) 303-315. doi: 10.1211/0022357011775532. 826 
[67] S.A. Surwase, L. Itkonen, J. Aaltonen, D. Saville, T. Rades, L. Peltonen, C.J. Strachan, 827 
Polymer incorporation method affects the physical stability of amorphous indomethacin in aqueous 828 
suspension, Eur. J. Pharm. Biopharm. 96 (2015) 32-43. doi: 10.1016/j.ejpb.2015.06.005. 829 
[68] R. Paus, A. Prudic, Y. Ji, Influence of excipients on solubility and dissolution of 830 
pharmaceuticals, Int. J. Pharm. 485 (2015) 277-287. doi: 10.1016/j.ijpharm.2015.03.004. 831 
[69] R.J. Chokshi, N.H. Shah, H.K. Sandhu, A.W. Malick, H. Zia, Stabilization of low glass 832 
transition temperature indomethacin formulations: Impact of polymer-type and its concentration, J. 833 
Pharm. Sci. 97 (2008) 2286-2298. doi: 10.1002/jps.21174. 834 
[70] W. Zhang, C. Zhang, Y. He, B. Duan, G. Yang, W. Ma, Y. Zhang, Factors Affecting the 835 
Dissolution of Indomethacin Solid Dispersions, AAPS PharmSciTech 18 (2017) 3258-3273. doi: 836 
10.1208/s12249-017-0813-2. 837 
[71] N.M. Najib, M. Suleiman, A. Malakh, Characteristics of the in vitro release of ibuprofen from 838 
polyvinylpyrrolidone solid dispersions, Int. J. Pharm. 32 (1986) 229-236. doi: 10.1016/0378-839 
5173(86)90183-3. 840 
[72] K. Löbmann, R. Laitinen, C. Strachan, T. Rades, H. Grohganz, Amino acids as co-amorphous 841 
stabilizers for poorly water-soluble drugs-Part 2: molecular interactions, Eur. J. Pharm. Biopharm. 842 
85 (2013) 882-888. doi: 10.1016/j.ejpb.2013.03.026. 843 
[73] M.A. El-Hinnawi, N.M. Najib, Ibuprofen-polyvinylpyrrolidone dispersions. Proton nuclear 844 
magnetic resonance and infrared studies, Int. J. Pharm. 37 (1987) 175-177. doi: 10.1016/0378-845 
5173(87)90024-X. 846 
[74] N.M. Najib, M.A. El-Hinnawi, M.S. Suleiman, Physicochemical characterization of ibuprofen-847 
polyvinylpyrrolidone dispersions, Int. J. Pharm. 45 (1988) 139-144. doi: 10.1016/0378-848 
5173(88)90042-7. 849 
[75] Z. Gashi, R. Censi, L. Malaj, R. Gobetto, M. Mozzicafreddo, M. Angeletti, A. Masic, P. Di 850 
Martino, Differences in the interaction between aryl propionic acid derivatives and 851 
poly(vinylpyrrolidone) K30: A multi-methodological approach, J. Pharm. Sci. 98 (2009) 4216-852 
4228. doi: 10.1002/jps.21734. 853 
[76] L. Malaj, R. Censi, M. Mozzicafreddo, L. Pellegrino, M. Angeletti, R. Gobetto, P. Di Martino, 854 
Influence of relative humidity on the interaction between different aryl propionic acid derivatives 855 
and poly(vinylpyrrolydone) K30: Evaluation of the effect on drug bioavailability, Int. J. Pharm. 398 856 
(2010) 61-72. doi: 10.1016/j.ijpharm.2010.07.024. 857 
34 
 
[77] K.P.R. Chowdary, D. Udaya Chandra, V. Parimala, M. Indira, A factorial study on formulation 858 
development of ibuprofen tablets employing starch 1500 and PVP K 30, Int. J. Pharm. Sci. Res. 3 859 
(2012) 189-193. doi: 10.13040/IJPSR.0975-8232.3(1).189-93 860 
[78] H. Chauhan, A. Kuldipkumar, T. Barder, A. Medek, C.H. Gu, E. Atef, Correlation of 861 
inhibitory effects of polymers on indomethacin precipitation in solution and amorphous solid 862 
crystallization based on molecular interaction, Pharm. Res. 31 (2014) 500-515. doi: 863 
10.1007/s11095-013-1178-1. 864 
[79] D. Prasad, H. Chauhan, E. Atef, Amorphous stabilization and dissolution enhancement of 865 
amorphous ternary solid dispersions: Combination of polymers showing drug-polymer interaction 866 
for synergistic effects, J. Pharm. Sci. 103 (2014) 3511-3523. doi: 10.1002/jps.24137. 867 
[80] D. Prasad, H. Chauhan, E. Atef, Role of Molecular Interactions for Synergistic Precipitation 868 
Inhibition of Poorly Soluble Drug in Supersaturated Drug-Polymer-Polymer Ternary Solution, Mol. 869 
Pharm. 13 (2016) 756-765. doi: 10.1021/acs.molpharmaceut.5b00655. 870 
[81] D.D. Patel, B.D. Anderson, Adsorption of Polyvinylpyrrolidone and its Impact on Maintenance 871 
of Aqueous Supersaturation of Indomethacin via Crystal Growth Inhibition, J. Pharm. Sci. 104 872 
(2015) 2923-2933. doi: 10.1002/jps.24493. 873 
[82] D. Hirai, Y. Iwao, S.I. Kimura, S. Noguchi, S. Itai, Mathematical model to analyze the 874 
dissolution behavior of metastable crystals or amorphous drug accompanied with a solid-liquid 875 
interface reaction, Int. J. Pharm. 522 (2017) 58-65. doi: 10.1016/j.ijpharm.2017.02.050. 876 
[83] G. Kasten, K. Nouri, H. Grohganz, T. Rades, K. Löbmann, Performance comparison between 877 
crystalline and co-amorphous salts of indomethacin-lysine, Int. J. Pharm. 533 (2017) 138-144. doi: 878 
10.1016/j.ijpharm.2017.09.063 879 
[84] I. Petry, K. Löbmann, H. Grohganz, T. Rades, C.S. Leopold, Undesired co-amorphisation of 880 
indomethacin and arginine during combined storage at high humidity conditions, Int. J. Pharm. 544 881 
(2018) 172-180. doi: 10.1016/j.ijpharm.2018.04.026. 882 
[85] H. Sekizaki, K. Danjo, H. Eguchi, Y. Yonezawa, H. Sunada, A. Otsuka, Solid-State Interaction 883 
of Ibuprofen with Polyvinylpyrrolidone, Chem. Pharm. Bull. 43 (1995) 988-993. doi: 884 
10.1248/cpb.43.988. 885 
[86] S. Bogdanova, I. Pajeva, P. Nikolova, I. Tsakovska, B. Müller, Interactions of 886 
poly(vinylpyrrolidone) with ibuprofen and naproxen: Experimental and modeling studies, Pharm. 887 
Res. 22 (2005) 806-815. doi: 10.1007/s11095-005-2598-3. 888 
[87] E. Courvoisier, P.A. Williams, G. K. Lim, C.E. Hughes, K.D.M. Harris, CCDC 855058: 889 
Experimental Crystal Structure Determination, 2014, doi: 10.5517/ccxprjv 890 
[88] M. Woinska, S. Grabowsky, P.M. Dominiak, K. Woźniak, D. Jayatilaka, CCDC 1423912: 891 
Experimental Crystal Structure Determination, 2016, doi: 10.5517/ccdc.csd.cc1jspnn 892 
[89] F.R. Fronczek, H.N. Kamel, M. Slattery, CCDC 224658: Experimental Crystal Structure 893 
Determination, 2014, doi: 10.5517/cc7js1k 894 
35 
 
[90] F.R.Fronczek, H.N. Kamel, M. Slattery CCDC 224659: Experimental Crystal Structure 895 
Determination, 2014, DOI: 10.5517/cc7js2l 896 
[91] E. Courvoisier, P.A. Williams, G.K. Lim, C.E. Hughes, K.D.M. Harris, The crystal structure of 897 
L-arginine, Chem. Commun. 48 (2012) 2761-2763. doi: 10.1039/c2cc17203h. 898 
[92] M. Woinska, S. Grabowsky, P.M. Dominiak, K. Wozniak, D. Jayatilaka, Hydrogen atoms can 899 
be located accurately and precisely by x-ray crystallography, Sci. Adv. 2 (2016). doi: 900 
10.1126/sciadv.1600192. 901 
[93] F.R. Fronczek, H.N. Kamel, M. Slattery, Three polymorphs (alpha, beta and delta) of D-902 
mannitol at 100 K, Acta Crystallogr. C 59 (2003) 567-560. doi: 10.1107/S0108270103018961. 903 
[94] P.J. Cox, P.L. Manson, CCDC 217467: Experimental Crystal Structure Determination, 2014, 904 
doi: 10.5517/cc7992w 905 
[95] K. Ostrowska, M. Kropidlowska, A. Katrusiak, CCDC 1041383: Experimental Crystal 906 
Structure Determination, 2015, doi: 10.5517/cc13yn0q 907 
[96] P.J. Cox, P.L. Manson, gamma-indomethacin at 120 K, Acta Crystallogr. Sect. E Struct. Rep 908 
Online 59 (2003) 986-988. doi: 10.1107/S160053680301290X 909 
[97] K. Ostrowska, M. Kropidlowska, A. Katrusiak, High-Pressure Crystallization and Structural 910 
Transformations in Compressed R,S-Ibuprofen, Cryst. Growth Des. 15 (2015) 1512-1517. doi: 911 
10.1021/cg5018888. 912 
[98] S.A. Surwase, J.P. Boetker, D. Saville, B.J. Boyd, K.C. Gordon, L. Peltonen, C.J. Strachan, 913 
Indomethacin: New Polymorphs of an Old Drug, Mol. Pharm. 10 (2013) 4472-4480. doi: 914 
10.1021/mp400299a. 915 
[99] M.L. Vueba, M.E. Pina, De Carvalho, L A E Batista, Conformational stability of ibuprofen: 916 
Assessed by DFT calculations and optical vibrational spectroscopy, J. Pharm. Sci. 97 (2008) 845-917 
859. doi: 10.1002/jps.21007. 918 
[100] J. Breitenbach, W. Schrof, J. Neumann, Confocal Raman-spectroscopy: Analytical approach 919 
to solid dispersions and mapping of drugs, Pharm. Res. 16 (1999) 1109-1113. doi: 920 
10.1023/A:1018956304595. 921 
[101] L.S. Taylor, F.W. Langkilde, G. Zografi, Fourier transform Raman spectroscopic study of the 922 
interaction of water vapor with amorphous polymers, J. Pharm. Sci. 90 (2001) 888-901. doi: 923 
10.1002/jps.1041. 924 
[102] S.L. Wunder, M.I. Bell, G. Zerbi, Band Broadening of CH2 Vibrations in the Raman-Spectra 925 
of Polymethylene Chains, J. Chem. Phys. 85 (1986) 3827-3839. doi: 10.1063/1.450903. 926 
[103] J. Barra, F. Falson-Rieg, E. Doelker, Influence of the organization of binary mixes on their 927 
compactibility, Pharm. Res. 16 (1999) 1449-1455. doi: 10.1023/A:1018967529128. 928 
36 
 
[104] M.N. Slipchenko, H. Chen, D.R. Ely, Y. Jung, M.T. Carvajal, J. Cheng, Vibrational imaging 929 
of tablets by epi-detected stimulated Raman scattering microscopy, Analyst 135 (2010) 2613-2619. 930 
doi: 10.1039/c0an00252f. 931 
 LIST OF FIGURES AND TABLES 932 
Tables 933 
Table 1. The compositions of different tablet formulations determined by DoE. 934 
Tablet 
identifier 
Amount of IBU-ARG 
(amount of IBU) 
Amount 
of PVP  
Sugar 
alcohol* 
Tablet 
mass 
B1 92.2 mg (50 mg) 30.7 mg Xylitol 307.3 mg 
B2 138.3 mg (75 mg) 30.7 mg Xylitol 422.5 mg 
B3 92.2 mg (50 mg) 30.7 mg Mannitol 307.3 mg 
B4 138.3 mg (75 mg) 30.7 mg Mannitol 422.5 mg 
B5 92.2 mg (50 mg) 46.1 mg Xylitol 345.8 mg 
B6 138.33 mg (75 mg) 46.1 mg Xylitol 461.1 mg 
B7 92.2 mg (50 mg) 46.1 mg Mannitol 345.8 mg 
B8 138.33 mg (75 mg) 46.1 mg Mannitol 461.1 mg 
B9 115.3 mg (62.5 mg) 38.4 mg Xylitol 384.3 mg 
   
Tablet 
identifier 
Amount of IND-ARG 
(amount of IND) 
Amount 
of PVP  
Sugar 
alcohol* 
Tablet 
mass 
N1 74.3 mg (50 mg) 24.8 mg Mannitol 247.8 mg 
N2 111.5 mg (75 mg) 24.8 mg Mannitol 340.8 mg 
N3 74.3 mg (50 mg) 38.5 mg Mannitol 282.0 mg 
N4 111.5 mg (75 mg) 38.5 mg Mannitol 375.0 mg 
N5 74.3 mg (50 mg) 24.8 mg Xylitol 247.8 mg 
N6 111.5 mg (75 mg) 24.8 mg Xylitol 340.8 mg 
N7 74.3 mg (50 mg) 38.5 mg Xylitol 282.0 mg 
N8 111.5 mg (75 mg) 38.5 mg Xylitol 375.0 mg 
N9 92.9 mg (62.5 mg) 31.65 mg Mannitol 311.4 mg 
*Neither mannitol or xylitol have been shown to undertake Maillard 
reactions [39] 
 935 
Figures 936 
 937 
Fig. 1. Scanning electron microscope images of the spray dried ibuprofen-arginine (A) and 938 
indomethacin-arginine (B) mixtures. 939 
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 940 
Fig. 2. The normalized coefficient plots of the models describing the effect of the amount of co-941 
amorphous ibuprofen-arginine (IBU-ARG) or indomethacin-arginine (IND-ARG) salt, the amount 942 
of PVP and the sugar alcohol species (mannitol OR xylitol) on the mechanical properties of the 943 
tablets. 944 
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 945 
Fig. 3. The interaction plots of models describing the effect of changes in tablet composition on the 946 
tensile strength of N formulations (1.) as well as on the 1/C value of B formulations (2.) and N 947 
formulations (3.). 948 
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 949 
Fig. 4. Dissolution profiles of A. IBU-ARG and xylitol containing tablets in pH 1.2, B. IBU-ARG 950 
and mannitol containing tablets in pH 1.2, C. IND-ARG and xylitol containing tablets in pH 5.0 and 951 
D. IND-ARG and mannitol containing tablets in pH 5.0. The drug doses in different formulations 952 
were 50 mg (B1, B3, B5, B7, N1, N3, N5, N7), 62.5 mg (B9, N9) or 75 mg (B2, B4, B6, B8, N2, 953 
N4, N6, N8). 954 
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 955 
Fig. 5. The interaction plots of models predicting the effect of the tablet composition on the 956 
CDA15min of B formulations (1.) as well as on the AUC0-120min (2.) and CDA15min (3.) of N 957 
formulations. 958 
 959 
Fig. 6. The normalized coefficient plots of the models describing the effect of the amount of co-960 
amorphous ibuprofen-arginine (IBU-ARG) or indomethacin-arginine (IND-ARG) salt, the amount 961 
of PVP and the sugar alcohol species (mannitol or xylitol) on the area under the cumulative 962 
dissolved drug amount-time curve between 0 and 120 minutes (AUC0-120min) and on the 963 
cumulative dissolved drug amount after 15 minutes (CDA15min). 964 
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 965 
Fig. 7. The investigation of the effect of arginine (ARG) and the formation of co-amorphous salt 966 
(CA) on the release of ibuprofen (IBU) and indomethacin (IND) from B4- and N2-formulations (A 967 
and B, respectively) as well as the effect of polyvinylpyrrolidone K30 (PVP) on the supersaturation 968 
stability after drug release from B4- and N2-formulations (C and D, respectively). PM denotes 969 
physical mixture and Cryst crystalline drug.  970 
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 971 
Fig. 8. The X-ray diffractograms (A) an FTIR spectra (B) of B2-, B4-, N2- and N6-formulations at 972 
day 0 and after storage under ambient temperature and 33% relative humidity. With formulations 973 
that showed no signs of recrystallization, only the data from the beginning and end of the study are 974 
shown, but with B2 formulation the data from several time points is included. The diffractograms of 975 
mannitol and xylitol are also included for comparison.    976 
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 977 
Fig. 9. The PCA based CARS images of tablet surfaces of B4- and B2- formulations (left column, 978 
A,D,G,J), corresponding the overlaid CARS/SFG/SHG images (at 1652 cm-1) (middle column, 979 
B,E,H,K) and CARS spectra extracted from regions marked with white arrows and numbers (right 980 
column, C,F,I,L) on day 0 and on week 20. The PCA RGB image is generated from a CARS 981 
44 
 
spectral scan in the region 1417−1804 cm−1, using the score values of the first three PCs. PCA 982 
loadings are shown in Figure S8. The scale bar is 80 µm. 983 
